Nachrichten
bioMérieux receives De Novo FDA Authorization for its BIOFIRE® Joint Infection (JI) Panel
04 Mai, 2022Joint infections (“septic arthritis”) are serious infections involving either native or prosthetic joints. They are medical emergencies which can occur at all ages, and can lead to functional joint impairment, long-lasting disability, and may even be life-threatening. The number of prosthetic...
bioMérieux – First-Half 2016 Results
31 August, 2016
bioMérieux – Second-Quarter 2016 Business Review
18 Juli, 2016
bioMérieux enlarges its pathogen identification capability on VITEK® MS
06 Juli, 2016
With a database of more than 15,000 strains VITEK® MS improves clinical decision-making for infectious diseases
bioMerieux Receives FDA Clearance for Expanded Use of VIDAS® B•R•A•H•M•S PCT™ Test for Managing Sepsis Patients with Elevated Risk of Mortality
01 Juli, 2016
Tracking PCT – a biomarker for bacterial infections – over time provides strong indication of likely mortality, enabling physicians to personalize care for high-risk patients
bioMérieux acquires Hyglos
01 Juni, 2016
bioMérieux acquires Hyglos and expands its offering to the detection of endotoxins in pharmaceutical products
bioMérieux and the Lyon Civil Hospitals strengthen their collaboration
31 Mai, 2016
bioMérieux and the Lyon Civil Hospitals strengthen their collaboration and expand their partnership to include Claude Bernard University Lyon 1 Two joint research laboratories focused on a common goal: advancing medical research for the benefit of patients
bioMérieux and Antwerp University unveil the final results of the first Global Point Prevalence Survey1 of antibiotic use and resistance rates in hospitals
11 April, 2016
Huge discrepancies in antibiotic use practices between countries 2nd line antibiotics2 too frequently prescribed
bioMérieux – 2015 Financial Results
02 März, 2016
Fourth-Quarter 2015 Business Review
21 Januar, 2016